ES2955019T3 - Composiciones de hierro novedosas y métodos para preparar y utilizar las mismas - Google Patents
Composiciones de hierro novedosas y métodos para preparar y utilizar las mismas Download PDFInfo
- Publication number
- ES2955019T3 ES2955019T3 ES20717359T ES20717359T ES2955019T3 ES 2955019 T3 ES2955019 T3 ES 2955019T3 ES 20717359 T ES20717359 T ES 20717359T ES 20717359 T ES20717359 T ES 20717359T ES 2955019 T3 ES2955019 T3 ES 2955019T3
- Authority
- ES
- Spain
- Prior art keywords
- iron
- composition
- aqueous
- sucrose
- samples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 108
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims description 27
- 230000001681 protective effect Effects 0.000 claims abstract description 7
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 claims description 28
- 229940032961 iron sucrose Drugs 0.000 claims description 28
- 210000003734 kidney Anatomy 0.000 claims description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 9
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 7
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 claims description 7
- 229950003776 protoporphyrin Drugs 0.000 claims description 7
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000008365 aqueous carrier Substances 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000005484 gravity Effects 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 19
- 229930006000 Sucrose Natural products 0.000 abstract description 19
- 239000005720 sucrose Substances 0.000 abstract description 19
- DKIDFDYBDZCAAU-UHFFFAOYSA-L carbonic acid;iron(2+);carbonate Chemical compound [Fe+2].OC([O-])=O.OC([O-])=O DKIDFDYBDZCAAU-UHFFFAOYSA-L 0.000 abstract description 4
- 239000000523 sample Substances 0.000 description 39
- 238000009826 distribution Methods 0.000 description 22
- 239000000463 material Substances 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 238000005227 gel permeation chromatography Methods 0.000 description 16
- 239000002245 particle Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000002441 X-ray diffraction Methods 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 229940035081 venofer Drugs 0.000 description 8
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000002296 dynamic light scattering Methods 0.000 description 6
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 238000009616 inductively coupled plasma Methods 0.000 description 5
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 5
- 238000002411 thermogravimetry Methods 0.000 description 5
- 238000003221 volumetric titration Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 4
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 4
- -1 Iron carbohydrate Chemical class 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229910021519 iron(III) oxide-hydroxide Inorganic materials 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- 238000012764 semi-quantitative analysis Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000003991 Rietveld refinement Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000003921 particle size analysis Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- MFBBZTDYOYZJGB-HAONTEFVSA-L (2s,3s,4s,5r)-4-[(2r,3r,4r,5s,6r)-5-[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanoate;iron(3+);oxyg Chemical compound O.[OH-].[O-2].[Fe+3].O[C@@H]1[C@@H](O)[C@@H](O[C@@H]([C@H](O)CO)[C@@H](O)[C@H](O)C([O-])=O)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 MFBBZTDYOYZJGB-HAONTEFVSA-L 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000008015 Hemeproteins Human genes 0.000 description 2
- 108010089792 Hemeproteins Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- CUPCBVUMRUSXIU-UHFFFAOYSA-N [Fe].OOO Chemical compound [Fe].OOO CUPCBVUMRUSXIU-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000001636 atomic emission spectroscopy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960004131 ferric carboxymaltose Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229910052598 goethite Inorganic materials 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- AEIXRCIKZIZYPM-UHFFFAOYSA-M hydroxy(oxo)iron Chemical compound [O][Fe]O AEIXRCIKZIZYPM-UHFFFAOYSA-M 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 2
- 229940090441 infed Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002505 iron Chemical class 0.000 description 2
- 229940097452 iron sucrose injection Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000001998 small-angle neutron scattering Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 229910002588 FeOOH Inorganic materials 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000003070 Statistical process control Methods 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 238000005102 attenuated total reflection Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- MSNWSDPPULHLDL-UHFFFAOYSA-K ferric hydroxide Chemical group [OH-].[OH-].[OH-].[Fe+3] MSNWSDPPULHLDL-UHFFFAOYSA-K 0.000 description 1
- 229940042644 ferrlecit Drugs 0.000 description 1
- 229940102709 ferumoxytol Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940019742 injectafer Drugs 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000002707 nanocrystalline material Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 229940062350 sodium ferric gluconate complex Drugs 0.000 description 1
- UDJMEHOEDIAPCK-UHFFFAOYSA-N sodium iron(2+) oxygen(2-) Chemical compound [O-2].[Fe+2].[Na+] UDJMEHOEDIAPCK-UHFFFAOYSA-N 0.000 description 1
- MQBDAEHWGRMADS-XNHLMZCASA-M sodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [O-2].[O-2].[O-2].[Na+].[Fe+3].[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MQBDAEHWGRMADS-XNHLMZCASA-M 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812028P | 2019-02-28 | 2019-02-28 | |
| PCT/US2020/020517 WO2020176894A1 (en) | 2019-02-28 | 2020-02-28 | Novel iron compositions and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2955019T3 true ES2955019T3 (es) | 2023-11-28 |
Family
ID=70190086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20717359T Active ES2955019T3 (es) | 2019-02-28 | 2020-02-28 | Composiciones de hierro novedosas y métodos para preparar y utilizar las mismas |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11292813B2 (https=) |
| EP (2) | EP3930686B1 (https=) |
| JP (3) | JP7320611B2 (https=) |
| KR (1) | KR20210133243A (https=) |
| CN (2) | CN119488480A (https=) |
| AU (2) | AU2020229381A1 (https=) |
| CA (1) | CA3131596A1 (https=) |
| DK (1) | DK3930686T3 (https=) |
| ES (1) | ES2955019T3 (https=) |
| FI (1) | FI3930686T3 (https=) |
| HR (1) | HRP20230989T1 (https=) |
| HU (1) | HUE063182T2 (https=) |
| LT (1) | LT3930686T (https=) |
| PL (1) | PL3930686T3 (https=) |
| PT (1) | PT3930686T (https=) |
| RS (1) | RS64652B1 (https=) |
| SG (1) | SG11202109323UA (https=) |
| SI (1) | SI3930686T1 (https=) |
| SM (1) | SMT202300276T1 (https=) |
| WO (1) | WO2020176894A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022056378A1 (en) * | 2020-09-11 | 2022-03-17 | Renibus Therapeutics, Inc. | Method for treating cancer with kidney protection |
| WO2024069644A1 (en) * | 2022-09-30 | 2024-04-04 | West Bengal Chemical Industries Limited | A pharmaceutically acceptable ferric carboxymaltose and preparation thereof |
| CN115969714B (zh) * | 2022-11-03 | 2025-03-11 | 华熙生物科技股份有限公司 | 具有光谱选择性的防晒组合物及其应用 |
| WO2025047574A1 (ja) | 2023-08-29 | 2025-03-06 | 株式会社ダイセル | 硬化性エポキシ組成物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE862482C (de) * | 1950-05-14 | 1953-01-12 | Merck Chem Fab E | Verfahren zur Darstellung haltbarer, injizierbarer Loesungen von Salzen des dreiwertigen Eisens |
| US5624668A (en) | 1995-09-29 | 1997-04-29 | Luitpold Pharmaceuticals, Inc. | Iron dextran formulations |
| DE19547356A1 (de) * | 1995-12-19 | 1997-06-26 | Vifor Int Ag | Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung |
| US20030232738A1 (en) * | 1998-04-20 | 2003-12-18 | National Jewish Medical And Research Center | Method and composition for increasing CD4+ T lymphocyte immune responsiveness |
| CA2365787C (en) * | 2000-12-20 | 2006-02-14 | Dialysis Solutions Inc. | Sterile low bicarbonate dialysis concentrate solutions |
| WO2004019032A1 (en) * | 2002-08-26 | 2004-03-04 | Luitpold Pharmaceuticals, Inc. | Bioequivalence test for iron-containing formulations |
| WO2005094202A2 (en) * | 2004-03-16 | 2005-10-13 | Navinta, Llc | Iron sucrose complexes and method of manufacture thereof |
| EP1819720B1 (en) | 2004-12-06 | 2013-05-15 | Emcure Pharmaceuticals Limited | A cost-effective process for preparation of manufacture of iron sucrose |
| ITMO20050056A1 (it) | 2005-03-15 | 2006-09-16 | Biofer Spa | Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi. |
| CN100528237C (zh) | 2005-04-26 | 2009-08-19 | 重庆医药工业研究院有限责任公司 | 多核的氢氧化铁-糖复合物的制备方法 |
| EP1757299A1 (de) * | 2005-08-25 | 2007-02-28 | Vifor (International) Ag | Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung |
| US7960371B2 (en) | 2006-10-04 | 2011-06-14 | Infacare Pharmaceutical Corporation | High-purity large-scale preparation of stannsoporfin |
| EP1947120A1 (de) | 2007-01-19 | 2008-07-23 | Vifor (International) Ag | Eisen-Kohlenhydrat-Komplex-Verbindungen |
| IN269965B (https=) | 2007-06-25 | 2015-11-27 | Claris Lifescienses Ltd | |
| TWI592159B (zh) | 2007-11-16 | 2017-07-21 | 威佛（國際）股份有限公司 | 藥學組成物 |
| AR076070A1 (es) * | 2009-03-02 | 2011-05-18 | Vifor Int Ag | Absorbente de fosfato para el tratamiento de la hiperfosfatemia |
| CN102451185A (zh) * | 2010-10-19 | 2012-05-16 | 长春纳米生技公司 | 金属离子纳米簇组合物 |
| EP2548562A1 (de) | 2011-07-18 | 2013-01-23 | SeBo GmbH | Kombinationstherapie mit Eisen-basierenden Phosphatadsorbern |
| EP2647389A1 (en) * | 2012-04-04 | 2013-10-09 | Charité - Universitätsmedizin Berlin | Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use |
| CN103340827B (zh) | 2013-07-16 | 2014-12-10 | 成都天台山制药有限公司 | 蔗糖铁注射液及其制法 |
| CN104558064A (zh) | 2013-10-29 | 2015-04-29 | 北京京卫信康医药科技发展有限公司 | 蔗糖铁的制备方法 |
| IN2013CH05383A (https=) | 2013-11-21 | 2015-08-28 | Reddy’S Lab Ltd Dr | |
| CN104098616B (zh) | 2014-05-27 | 2016-04-20 | 广西壮族自治区化工研究院 | 一种蔗糖铁的制备方法 |
| SI3200582T1 (sl) * | 2014-09-29 | 2024-04-30 | Fred Hutchinson Cancer Center | Sestave, kompleti in metode za indukcijo pridobljene citorezistence z uporabo induktorjev stresnih proteinov |
| WO2017165692A1 (en) * | 2016-03-23 | 2017-09-28 | Fred Hutchinson Cancer Research Center | Compounds linked with a saccharide metal complex and uses thereof |
| US20190358242A1 (en) * | 2017-02-08 | 2019-11-28 | Fred Hutchinson Cancer Research Center | Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers |
| HUE070809T2 (hu) | 2017-09-11 | 2025-07-28 | Pharmacosmos Holding As | Vaskomplex vegyületek gyógyászati alkalmazásra |
| CN109912675B (zh) | 2017-12-13 | 2020-09-15 | 北京市林业果树科学研究院 | 一种蔗糖亚铁及其制备方法 |
| CN110063965A (zh) | 2019-06-04 | 2019-07-30 | 吉林省富生医疗器械有限公司 | 一种血液透析浓缩物 |
| CN112315902B (zh) | 2019-08-05 | 2022-05-13 | 南京恒生制药有限公司 | 一种低易变铁含量蔗糖铁注射液制备方法 |
| CN112168844A (zh) | 2020-09-29 | 2021-01-05 | 神奈纳米医药技术(珠海)有限公司 | 一种氢氧化铁碳水化合物复合物的制备方法 |
| MY210100A (en) | 2020-09-29 | 2025-08-27 | Lg Bionano Llc | Methods of preparing iron complexes |
| CN112156109A (zh) | 2020-09-29 | 2021-01-01 | 神奈纳米医药技术(珠海)有限公司 | 氢氧化铁-糖络合物的制备方法及其应用 |
| CN115531414A (zh) | 2021-06-30 | 2022-12-30 | 南京恒生制药有限公司 | 一种新型蔗糖铁复合物及其制备方法 |
| CN118103047A (zh) | 2021-08-27 | 2024-05-28 | 美国瑞根特有限公司 | 铁组合物及其制备和使用方法 |
-
2020
- 2020-02-28 CN CN202411305791.9A patent/CN119488480A/zh active Pending
- 2020-02-28 EP EP20717359.2A patent/EP3930686B1/en active Active
- 2020-02-28 AU AU2020229381A patent/AU2020229381A1/en not_active Abandoned
- 2020-02-28 PL PL20717359.2T patent/PL3930686T3/pl unknown
- 2020-02-28 JP JP2021550178A patent/JP7320611B2/ja active Active
- 2020-02-28 ES ES20717359T patent/ES2955019T3/es active Active
- 2020-02-28 FI FIEP20717359.2T patent/FI3930686T3/fi active
- 2020-02-28 SG SG11202109323UA patent/SG11202109323UA/en unknown
- 2020-02-28 US US16/805,223 patent/US11292813B2/en active Active
- 2020-02-28 CA CA3131596A patent/CA3131596A1/en active Pending
- 2020-02-28 HR HRP20230989TT patent/HRP20230989T1/hr unknown
- 2020-02-28 KR KR1020217030370A patent/KR20210133243A/ko active Pending
- 2020-02-28 LT LTEPPCT/US2020/020517T patent/LT3930686T/lt unknown
- 2020-02-28 WO PCT/US2020/020517 patent/WO2020176894A1/en not_active Ceased
- 2020-02-28 RS RS20230725A patent/RS64652B1/sr unknown
- 2020-02-28 DK DK20717359.2T patent/DK3930686T3/da active
- 2020-02-28 CN CN202080031484.XA patent/CN113825496B/zh active Active
- 2020-02-28 SI SI202030257T patent/SI3930686T1/sl unknown
- 2020-02-28 PT PT207173592T patent/PT3930686T/pt unknown
- 2020-02-28 EP EP23176202.2A patent/EP4234020A3/en active Pending
- 2020-02-28 HU HUE20717359A patent/HUE063182T2/hu unknown
- 2020-02-28 SM SM20230276T patent/SMT202300276T1/it unknown
-
2022
- 2022-02-15 US US17/672,072 patent/US11840552B2/en active Active
- 2022-11-02 US US17/979,490 patent/US11834471B2/en active Active
-
2023
- 2023-07-21 JP JP2023118851A patent/JP7646750B2/ja active Active
- 2023-09-07 US US18/243,584 patent/US20240002427A1/en active Pending
-
2025
- 2025-03-04 JP JP2025033475A patent/JP2025084949A/ja active Pending
- 2025-09-10 AU AU2025230678A patent/AU2025230678A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2955019T3 (es) | Composiciones de hierro novedosas y métodos para preparar y utilizar las mismas | |
| Jahn et al. | A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications | |
| Tarres et al. | Aqueous self‐assembly and cation selectivity of cobaltabisdicarbollide dianionic dumbbells | |
| CN104880428B (zh) | 一种胶体果胶铋或含胶体果胶铋制剂中铋含量的测定方法 | |
| Alanazi et al. | Selective and reliable fluorometric quantitation of anti-cancer drug in real plasma samples using nitrogen-doped carbon dots after MMIPs solid phase microextraction: Monitoring methotrexate plasma level | |
| Åberg et al. | 17O and 1H NMR study of the tetranuclear hydroxo zirconium complex in aqueous solution | |
| Singla et al. | Enhancing encapsulation of hydrophobic phyto-drugs naringenin and baicalein in polymeric nano-micelles | |
| Kästele et al. | 13C NMR spectroscopy as a tool for the in situ characterisation of iron-supplementing preparations | |
| Minzanova et al. | Synthesis and physicochemical properties of antianemic iron and calcium complexes with sodium polygalacturonate | |
| Raval et al. | Preparation, characterization, and in-vitro assessment of calixarene nanovesicles: a supramolecular based nano-carrier for paclitaxel drug delivery | |
| HK40066891B (en) | Novel iron compositions and methods of making and using the same | |
| HK40066891A (en) | Novel iron compositions and methods of making and using the same | |
| HK40098133A (en) | Novel iron compositions and methods of making and using the same | |
| HK40066204A (zh) | 新型铁组合物及其制造和使用方法 | |
| HK40066204B (zh) | 新型铁组合物及其制造和使用方法 | |
| Barot et al. | Physicochemical and toxicological characterization of sucrose-bound polynuclear iron oxyhydroxide formulations | |
| Lian et al. | The revolutionizing osteosarcoma therapy of carbon monoxide and doxorubicin synergy via mesoporous silica nanoparticles | |
| Jackson et al. | Solution equilibria and the X-ray structure of Cu (II) complexation with 3-amino-N-(pyridin-2-ylmethyl) propanamide, a pseudo-mimic of human serum albumin | |
| Yang et al. | Analysis on the interaction of coumarin isomers with human serum albumin in the presence of cisplatin | |
| Eriksson | Cerium Oxide Nanoparticles and Gadolinium Integration Synthesis, Characterization and Biomedical Applications | |
| Marcinkowska et al. | Cisplatin Derivatives and Their Complexes with PAMAM Dendrimers—A Way to Improve the Efficacy of Anticancer Drugs | |
| Zhang et al. | Self-assembly of a surfactant-encapsulated polyoxometalate mediated by coordination of metal ions | |
| Mejias | Characterization of titanium (IV)-transferrin binding interactions | |
| Cardona Mejías | Characterization of Ti (IV)-transferring binding interactions | |
| Bhai | Development and validation of analytical methods for estimation of citicoline in bulk and pharmaceutical formulations |